發(fā)布時(shí)間:
2021
-
07
-
20
點(diǎn)擊次數(shù):
0
所屬職位：
CEO
所屬公司：
甫康（上海）健康科技有限公司
個(gè)人簡(jiǎn)介：
沈孝坤博士，甫康藥業(yè)公司CEO，畢業(yè)于武漢大學(xué)醫(yī)學(xué)院獲得臨床醫(yī)學(xué)和生物科學(xué)雙學(xué)位，在中科院上海藥物研究所獲藥理學(xué)博士學(xué)位。先后在恒瑞、諾華等國(guó)內(nèi)外的知名企業(yè)從事過(guò)小分子和抗體新藥研發(fā)，有10多年新藥研發(fā)經(jīng)驗(yàn)，主導(dǎo)和參與過(guò)抗腫瘤、免疫、皮膚等多種疾病領(lǐng)域新藥的臨床開(kāi)發(fā)，并且?guī)椭鄠€(gè)藥物成功國(guó)內(nèi)上市，其中包括First-In-Class的IL-17 抗體蘇金單抗(Cosentyx)等。甫康藥業(yè)公司是一家處于臨床階段的生物醫(yī)藥公司，研發(fā)具備“First-In-Class”和“Best-in-Class”潛力的新療法，具備強(qiáng)大的新藥研發(fā)與臨床開(kāi)發(fā)能力，立足中國(guó)，面向全球。Dr. Shen Xiaokun, CEO of Convalife Pharmaceutical Co., Ltd., graduated from Wuhan University with degrees in clinical medicine and Bioscience, and obtained Ph.D degree in pharmacology from Shanghai Institute of Materia Medica, CAS. Dr. Shen has been engaged in the research and development of new drugs for small molecules and antibodies in Hengrui, Novartis and other well-known enterprises. Dr. Shen has more than 10 years of experience in the research and development of new drugs. He has led and participated ~10 projects in the clinical development of new drugs in the fields of anti-tumor, immunity, dermatology and other diseases. He has also helped several drugs to be successfully NDA in China, including first in class IL-17 antibody, Cosentyx, etc.Convalife originated from Latin “valere”, meaning “value and strong”Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies for cancer, autoimmune and infectious diseases to patients in China and around the world. Convalife develops new therapies with the potential of 'first in class' and 'best in class', and has strong new drug R & D and clinical development capabilities. Convalife obtained investment of famous listed companies such as Wuxibiologics (HK. 02269), Menovo Pharmaceutical (603538) etc.